GENETIC ENGINEERING AND MODEL SYSTEMS FOR ICC

Use of CRISPR/Cas9 for Modeling Genetic Alterations in ICC

CRISPR/Cas9 technology has emerged as a potent tool for simulating genetic modifications in iCCA, yielding significant insights into tumor biology and therapeutic advancement. CRISPR/Cas9 facilitates accurate genome editing, enabling researchers to induce specific mutations, like those in FGFR2, IDH1/2, and TP53, frequently linked to iCCA. This establishes precise in vitro and in vivo models that replicate the genetic profile of iCCA, facilitating the investigation of carcinogenesis, the identification of prospective therapeutic targets, and the evaluation of therapy responses [98]. Researchers can utilize CRISPR/Cas9 to create IDH1 mutations or FGFR2 fusions in hepatocyte or cholangiocyte cell lines, facilitating the investigation of how these modifications influence tumor initiation, development, and metastasis [99]. Moreover, these models enable the assessment of targeted medicines, such as FGFR inhibitors and IDH inhibitors, to determine their efficacy in a genetically pertinent setting.CRISPR/Cas9 models can enhance the comprehension of iCCA and expedite the identification of innovative treatment approaches.

Animal Models for Studying Genetic Mutations

Animal models play a crucial role in studying genetic mutations in iCCA, helping researchers understand tumorigenesis and test therapeutic strategies. Genetically engineered mouse models (GEMMs) allow for the introduction of specific mutations, such as those in IDH1/2, TP53, or FGFR2, commonly seen in iCCA [100]. These models closely mimic human iCCA's genetic landscape and tumor progression, providing insights into the molecular mechanisms driving the disease. Additionally, xenograft models, where human iCCA cells are implanted into immunocompromised mice, enable the evaluation of tumor growth and response to therapies. These models are also valuable for testing the efficacy of targeted treatments, such as IDH inhibitors or FGFR inhibitors. Overall, animal models provide essential tools for exploring genetic alterations in iCCA, facilitating the development of novel therapeutic approaches and improving our understanding of the disease's biology.

Patient-derived Organoids and Xenograft Models for Exploring ICC Genetics

Patient-derived organoids and xenograft models are potent instruments for investigating the genetics of iCCA. Organoids, originating from patient tumor tissue, replicate the architectural and genetic characteristics of the original tumor, facilitating individualized investigations of iCCA's genetic alterations and therapy responses [101]. Xenograft models, involving the implantation of human tumor cells into immunocompromised mice, enable researchers to monitor tumor proliferation and evaluate therapeutic approaches in vivo. Both models elucidate the genetic modifications propelling iCCA, including FGFR2 fusions and IDH mutations, and are crucial for formulating targeted therapeutics and comprehending tumor dynamics.